Lyra therapeutics announces closing of $50.0 million private placement

Watertown, mass., june 01, 2023 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (crs), today announced the closing of its previously announced private placement of common stock, pre-funded warrants to purchase common stock and purchase warrants to purchase common stock, resulting in gross proceeds of approximately $50.0 million. the private placement includes participation from new and existing investors, including perceptive advisors, venrock healthcare capital partners, armistice capital, surveyor capital (a citadel company), north bridge venture partners, nantahala capital, samsara biocapital, and woodline partners lp.
LYRA Ratings Summary
LYRA Quant Ranking